LTM1201LD (Brigham and Women's Hospital)

**LTM1201LD** is an investigational oral combination of **lorcaserin** and **cholecalciferol** evaluated by Brigham and Women's Hospital for obstructive sleep apnea. Lorcaserin is a serotonin 2C receptor agonist intended to increase hypoglossal motor output and upper-airway dilator-muscle activity during sleep, while cholecalciferol is converted to active vitamin D metabolites that activate the vitamin D receptor, which is expressed in hypoglossal motor nucleus neurons. The combination was studied as a pre-sleep pharmacologic approach to reduce upper-airway collapsibility and obstructive sleep apnea severity. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/52/NCT03640052/Prot_SAP_000.pdf))

Other names

lorcaserin + cholecalciferollorcaserin + vitamin D3